Gapping up
In reaction to strong earnings/guidance:
In reaction to strong earnings/guidance:
- SBLK +0.5%
M&A news:
- CAVM +7.5% (confirms deal to be acquired by Marvell (MRVL) for roughly $80/share)
- VALE +0.9% (to sell nitrogen and phosphate assets in Brazil to Yara; also upgraded to Outperform at RBC Capital Mkts)
Other news:
- DCIX +40.9% (continued volatility in pre-mkt)
- TOPS +8.4% (continued volatility in pre-mkt)
- EGLT +7.5% (received a grant from InnoBooster to develop a novel application of Guardian Technology)
- TSRO +7.3% (announces that the European Commission (EC) has granted marketing authorization for ZEJULA)
- ZIOP +7.2% (announces positive data updates supporting survival benefit and the underlying immune system mechanism for Ad-RTS-hIL-12 plus veledimex)
- DGLY +6.4% (announces 'significant development' in litigation against Axon Enterprise (AAXN))
- TOUR +5.9% (continued strength following last week's 20%+ gain)
- ITCI +5.4% (Receives FDA Fast Track Designation for Lumateperone for the Treatment of Schizophrenia)
- DBVT +5.2% (reports Topline Safety Results from REALISE Phase III Trial of Viaskin Peanut)
- ITUS +4.8% (entered into 3 mln share At-the-Market Issuance Sales Agreement with B. Riley FBR)
- DRYS +4.4% (shippers continued volatility in pre-mkt)
- EBS +3.3% (receives FDA approval to manufacture ACAM2000)
- ROKU +1.6% (continued volatility in pre-mkt)
Analyst comments:
- AEMD +6.2% (initiated with a Buy at H.C. Wainwright)
- ABLX +4.7% (initiated with a Overweight at JP Morgan)
- DLPH +1.3% (upgraded to Buy from Neutral at BofA/Merrill)
- VZ +0.9% (upgraded to Outperform from Market Perform at Wells Fargo)
- GM +0.8% (upgraded to Buy from Neutral at Guggenheim)